Literature DB >> 9744293

Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area.

M Di Mascio1, G Di Giovanni, V Di Matteo, S Prisco, E Esposito.   

Abstract

Electrophysiological techniques were used to study the effects of paroxetine, sertraline, and fluvoxamine on the basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of rats. Acute i.v. administrations of paroxetine (20-1280 microg/kg), sertraline (20-1280 microg/kg), and fluvoxamine (20-1280 microg/ kg) caused a slight but significant reduction in the firing rate of the VTA dopaminergic cells studied. Paroxetine produced a maximal inhibitory effect of 10 +/- 11% at the cumulative dose of 160 microg/kg. Sertraline induced a dose-related inhibition of VTA dopaminergic neurons, which reached its maximum (10 +/- 7%) at the cumulative dose of 1280 microg/kg. The effect of fluvoxamine on the basal firing rate of VTA dopaminergic neurons was more pronounced as compared to that of paroxetine and sertraline, in that it produced a maximal inhibition of 17 +/- 12% at the cumulative dose of 1280 microg/kg. Acute i.v. injections of paroxetine (20-1280 microg/kg), sertraline (20-1280 microg/kg), and fluvoxamine (20-5120 microg/kg) caused a dose-dependent decrease in the basal firing rate of serotonergic neurons in the dorsal raphe nucleus (DRN). Paroxetine and sertraline stopped the spontaneous firing of serotonergic neurons at the cumulative dose of 1280 microg/kg, whereas fluvoxamine reached the same effect only at the cumulative dose of 5120 microg/kg. Pretreatment with the 5-HTA1A receptor antagonist tertatolol (1 mg/kg, i.v.) reduced the inhibitory effects of paroxetine, fluvoxamine, and sertraline on the basal activity of serotonergic neurons in the DRN. Administration of tertatolol induced a 15-fold increase in the ED50 for fluvoxamine. The antagonistic effect of tertatolol was much less evident in blocking the inhibitory action exerted by paroxetine and sertraline on the activity of serotonergic neurons. Pretreatment with tertatolol (1 mg/kg, i.v.) potentiated the inhibitory effect of fluvoxamine on the basal activity of VTA dopaminergic neurons. Tertatolol did not affect the inhibitory action exerted by paroxetine and sertraline on these neurons. It is concluded that inhibition of the basal firing rate of dopaminergic neurons in the VTA is a common characteristic of selective serotonin reuptake inhibitors (SSRIs). The effects of SSRIs on VTA dopaminergic cell activity might be relevant for their therapeutic action and may explain the origin of the reported cases of akathisia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744293     DOI: 10.1016/s0361-9230(98)00054-9

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  21 in total

Review 1.  Developmental risk I: depression and the developing brain.

Authors:  John M Weir; Arthurine Zakama; Uma Rao
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2012-02-17

2.  Acute tramadol enhances brain activity associated with reward anticipation in the nucleus accumbens.

Authors:  Yuki Asari; Yumiko Ikeda; Amane Tateno; Yoshiro Okubo; Takehiko Iijima; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2018-06-27       Impact factor: 4.530

Review 3.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 4.  Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Authors:  Huailing Zhong; Nasser Haddjeri; Connie Sánchez
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

5.  Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.

Authors:  Emmanuelle Simon O'Brien; Rémi Legastelois; Hakim Houchi; Catherine Vilpoux; Stéphanie Alaux-Cantin; Olivier Pierrefiche; Etienne André; Mickaël Naassila
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

Review 6.  Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Authors:  Leonard L Howell; Kathryn A Cunningham
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area.

Authors:  Eliyahu Dremencov; Mostafa El Mansari; Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

8.  Fluvoxamine, a selective serotonin reuptake inhibitor, suppresses tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice.

Authors:  H Miura; H Qiao; T Kitagami; T Ohta; N Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2004-07-29       Impact factor: 4.530

9.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

10.  Role of 5-hydroxytryptamine2C receptors in Ca2+-dependent ethanol potentiation of GABA release onto ventral tegmental area dopamine neurons.

Authors:  Jonathan W Theile; Hitoshi Morikawa; Rueben A Gonzales; Richard A Morrisett
Journal:  J Pharmacol Exp Ther       Date:  2009-02-18       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.